Aseptia introduced its latest technological advancement to the marketplace at mid-July’s IFT16 Annual Meeting and Food Expo in Chicago. AseptiSense joins the company’s growing intellectual property portfolio as the first and only FDA-accepted solution for continuous-flow particulate validation.
AseptiSense uses surrogate food particles called BioPods to measure various aspects of a continuous-flow process system. BioPods capture data at up to 32 points along the processing line to give operators a look inside their validation. These game-changing tools and methods allow for successful simulation as well as particle-flow monitoring and safety validation. When used in conjunction with Aseptia’s patented AseptiWave—an award—winning microwave heating solution—the dual processing and validation technologies extend breakthrough commercial possibilities.
In late 2015, AseptiSense and AseptiWave discovered significant success as Aseptia received acceptance from the Food and Drug Administration (FDA) for the production and validation of aseptic products—including low acid products—containing particulates up to 5/8 inches using its patented system. This positive recommendation from the FDA—with no additional questions—followed extensive and careful examination, specifically regarding multiple particulates.
In conjunction with the introduction of AseptiSense, Aseptia takes advantage of IFT16 to rethink its brand. “We really wanted to get back to fundamentals,” says Aseptia CEO David Clark.
“At our core, we are a technology company,” he noted. “AseptiSense uses technology to take food producers inside their own processes. It really gets inside the pipes and shines a light into the shadows. That’s pretty powerful.”
Clark noted that AseptiWave’s heating technology—particularly in conjunction with AseptiSense—increasingly extends the possibilities for producers, including huge increases in throughput, significant decreases in downtime for changeover and maintenance as well as the ability to preserve the taste and nutritional quality of food items. “For certain producers, such as companies that use high-value ingredients, our offerings are second to none.”
Adds Clark, “Now our intellectual property portfolio delivers two robust options for multi-particulate production that can work separately or jointly. We’re excited about the future.”
